Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long NVO ETF

9.10
-0.0500-0.55%
Post-market: 9.06-0.0400-0.44%19:59 EDT
Volume:481.22K
Turnover:4.40M
Market Cap:35.29M
PE:- -
High:9.25
Open:9.25
Low:9.04
Close:9.15
52wk High:33.84
52wk Low:9.04
Shares:3.88M
Float Shares:3.88M
Volume Ratio:0.94
T/O Rate:12.41%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Novo Nordisk (0QIU) Receives a Hold from Berenberg Bank

TIPRANKS
·
Sep 22

Novo Nordisk Investors Remain Nervous, but Share Drop an Overreaction

Dow Jones
·
Sep 22

Novo Nordisk's Underwhelming Investor Day Met with Punishing Response

Dow Jones
·
Sep 22

Novo Nordisk's Share Fall After Investor Day Seems Harsh

Dow Jones
·
Sep 22

Novo Nordisk Investor Day Offered Little to Excite

Dow Jones
·
Sep 22

Novo Nordisk Highlights Building Blocks, but More Data Needed to Reassure Investors

Dow Jones
·
Sep 22

NYSE Net Change Percentage Gainers & Losers

Dow Jones
·
Sep 22

NYSE Most Active Issues

Dow Jones
·
Sep 22

Exchange Traded Funds Top 10 Percentage Losers

Dow Jones
·
Sep 22

European Stocks Close Higher Monday as Oil Prices Tumble

MT Newswires Live
·
Sep 22

Novo Nordisk A/S Series B Stock Falls Monday, Underperforms Market

Dow Jones
·
Sep 22

Top Midday Stories: Paramount Skydance Settles With US States to Pave Way for Warner Bros. Deal; Anthropic Now Eyeing November IPO

MT Newswires Live
·
Sep 21

Weight-Loss Drug Giant Sheds 13,000 Positions

Deep News
·
Sep 21

Novo Nordisk Details Progress on DKK 15 Billion Share Buyback Programme

TIPRANKS
·
Sep 21

European Equities Traded in the US as American depositary Receipts Rise in Monday Trading

MT Newswires Live
·
Sep 21

Cboe data shows mixed options sentiment in Novo Nordisk with shares down 7.85%

TIPRANKS
·
Sep 21

Novo Nordisk Says New Obesity Drug Outperformed Lilly's Zepbound in Phase 3 Trial

Dow Jones
·
Sep 21

Novo Nordisk A/S Stock (NVO) Moved Down by 7.86% on Sep 21: A Full Analysis

TradingKey
·
Sep 21

Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial

TIPRANKS
·
Sep 21

Sector Update: Healthcare

MT Newswires Live
·
Sep 21